PGH
MRSN

Partners Group Holding’s Mersana Therapeutics MRSN Stock Holding History

Partners Group Holding’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,499
Closed -$173K – 106
2022
Q2 		$173K Buy
+1,499
New +$141K 0.01% 108
2021
Q1 		– Sell
-1,635
Closed -$1.09M – 46
2020
Q4 		$1.09M Sell
1,635
-34
-2% -$18.9K 0.1% 39
2020
Q3 		$777K Buy
+1,669
New +$843K 0.09% 34

Other funds holding MRSN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Partners Group Holding's MRSN Position: Q3 2022 in Review

Partners Group Holding sold out of Mersana Therapeutics (MRSN) in Q3 2022, closing a stake of 1,499 shares — an estimated $173K sold.

Partners Group Holding first reported a position in MRSN in Q3 2020 and held it in 3 quarters. The position peaked at $1.09M in Q4 2020. 152 funds tracked by Wall St. Rank hold MRSN as of Q3 2022.

  • Partners Group Holding reported no remaining Mersana Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Partners Group Holding sold 1,499 Mersana Therapeutics shares in Q3 2022, an estimated $173K.
  • Partners Group Holding first reported a position in Mersana Therapeutics in Q3 2020 and held it in 3 quarters.
  • Partners Group Holding's Mersana Therapeutics position peaked at $1.09M in Q4 2020.
  • 152 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2022.

Based on Partners Group Holding's 13F filing for Q3 2022, filed 10 Nov 2022.